Induction of obliterative airway disease by anti-HLA class I antibodies.
Anti-HLA class I Abs are associated with the development of bronchiolitis obliterans syndrome (BOS) after lung transplantation. BOS is characterized histologically by fibrosis and airway epithelial cell apoptosis. We have previously shown that anti-HLA class I Abs induce proliferation, growth factor production and apoptosis in airway epithelial cells in vitro. Thus, this study was designed to determine whether anti-HLA class I Abs alone could induce obliterative airway disease (OAD) in heterotopic murine tracheal allografts. Toward this, HLA-A*0201-transgenic tracheal allografts were transplanted into Rag1-deficient mice treated with the W6/32 anti-HLA class I mAb. Allografts were harvested at days +30, +45, +60 and +90. Allografts displayed epithelial metaplasia by day +45, epithelial destruction and mild cellular infiltration by day +60 and complete lumen obliteration and moderate cellular infiltration by day +90. Anti-HLA class I Abs induced the production of several growth factors and growth factor receptors and apoptosis of parenchymal cells in the allograft. In addition, anti-HLA class I Abs induced macrophages and granulocytes infiltration. The results from this study demonstrate that anti-HLA class I Abs play an important role in the pathogenesis of OAD by inducing growth factor production, apoptosis and chemotaxis of inflammatory cells.
Maruyama
Takahiro
T
Department of Surgery, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Jaramillo
Andrés
A
Narayanan
Kishore
K
Higuchi
Toru
T
Mohanakumar
T
T
D000818:Animals; D000906:Antibodies / Q000494:pharmacology*; D017209:Apoptosis; D001989:Bronchiolitis Obliterans / Q000209:etiology; D049109:Cell Proliferation; D002633:Chemotaxis; D004847:Epithelial Cells / Q000166:cytology; D004848:Epithelium / Q000473:pathology; D005355:Fibrosis; D006098:Granulocytes / Q000378:metabolism; D006133:Growth Substances / Q000378:metabolism; D015234:HLA-A Antigens / Q000235:genetics; D015789:HLA-A2 Antigen; D015395:Histocompatibility Antigens Class I / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D007249:Inflammation; D016040:Lung Transplantation / Q000009:adverse effects; D008264:Macrophages / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008822:Mice, Transgenic; D008856:Microscopy, Fluorescence; D020411:Oligonucleotide Array Sequence Analysis; D029424:Pulmonary Disease, Chronic Obstructive / Q000209:etiology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D014132:Trachea / Q000473:pathology; D014180:Transplantation / Q000379:methods*; D014184:Transplantation, Homologous
D000906:Antibodies; D006133:Growth Substances; D015234:HLA-A Antigens; C435939:HLA-A*02:01 antigen; D015789:HLA-A2 Antigen; D015395:Histocompatibility Antigens Class I